Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Juni 2022 08:00 ET | Quelle: Ashvattha Therapeutics

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster...
05. Mai 2022 08:00 ET | Quelle: Ashvattha Therapeutics

Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022

REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics, (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey...
02. Mai 2022 14:00 ET | Quelle: Ashvattha Therapeutics

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

– Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects – – D-4517.2 exposure in healthy subjects translates to efficacious doses in choroidal...
27. April 2022 08:00 ET | Quelle: Ashvattha Therapeutics

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines

– Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum Alley Investments and Tribe Capital – – Exclusive product...

Vorherige Seite